375 related articles for article (PubMed ID: 22480256)
1. Targeting intracellular and extracellular alpha-synuclein as a therapeutic strategy in Parkinson's disease and other synucleinopathies.
Vekrellis K; Stefanis L
Expert Opin Ther Targets; 2012 Apr; 16(4):421-32. PubMed ID: 22480256
[TBL] [Abstract][Full Text] [Related]
2. Pathological roles of α-synuclein in neurological disorders.
Vekrellis K; Xilouri M; Emmanouilidou E; Rideout HJ; Stefanis L
Lancet Neurol; 2011 Nov; 10(11):1015-25. PubMed ID: 22014436
[TBL] [Abstract][Full Text] [Related]
3. Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease.
Azeredo da Silveira S; Schneider BL; Cifuentes-Diaz C; Sage D; Abbas-Terki T; Iwatsubo T; Unser M; Aebischer P
Hum Mol Genet; 2009 Mar; 18(5):872-87. PubMed ID: 19074459
[TBL] [Abstract][Full Text] [Related]
4. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
Olanow CW; Brundin P
Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
[TBL] [Abstract][Full Text] [Related]
5. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.
Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y
Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
[TBL] [Abstract][Full Text] [Related]
7. Targeting α-synuclein as a therapeutic strategy for Parkinson's disease.
Lawand NB; Saadé NE; El-Agnaf OM; Safieh-Garabedian B
Expert Opin Ther Targets; 2015; 19(10):1351-60. PubMed ID: 26135549
[TBL] [Abstract][Full Text] [Related]
8. Controlling the mass action of alpha-synuclein in Parkinson's disease.
Kim C; Lee SJ
J Neurochem; 2008 Oct; 107(2):303-16. PubMed ID: 18691382
[TBL] [Abstract][Full Text] [Related]
9. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
[TBL] [Abstract][Full Text] [Related]
10. The role of Ser129 phosphorylation of α-synuclein in neurodegeneration of Parkinson's disease: a review of in vivo models.
Sato H; Kato T; Arawaka S
Rev Neurosci; 2013; 24(2):115-23. PubMed ID: 23314528
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy targeting α-synuclein, with relevance for future treatment of Parkinson's disease and other Lewy body disorders.
Lindström V; Ihse E; Fagerqvist T; Bergström J; Nordström E; Möller C; Lannfelt L; Ingelsson M
Immunotherapy; 2014; 6(2):141-53. PubMed ID: 24491088
[TBL] [Abstract][Full Text] [Related]
12. Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies.
Oueslati A; Fournier M; Lashuel HA
Prog Brain Res; 2010; 183():115-45. PubMed ID: 20696318
[TBL] [Abstract][Full Text] [Related]
13. α-Synuclein-carrying extracellular vesicles in Parkinson's disease: deadly transmitters.
Chistiakov DA; Chistiakov AA
Acta Neurol Belg; 2017 Mar; 117(1):43-51. PubMed ID: 27473175
[TBL] [Abstract][Full Text] [Related]
14. Can Parkinson's disease pathology be propagated from one neuron to another?
Dunning CJ; Reyes JF; Steiner JA; Brundin P
Prog Neurobiol; 2012 May; 97(2):205-19. PubMed ID: 22115849
[TBL] [Abstract][Full Text] [Related]
15. Mathematical approach to understand the kinetics of alpha-synuclein aggregation: relevance to Parkinson's disease.
Bharathi P; Nagabhushan P; Rao KS
Comput Biol Med; 2008 Oct; 38(10):1084-93. PubMed ID: 18823621
[TBL] [Abstract][Full Text] [Related]
16. Dissecting the potential molecular mechanisms underlying alpha-synuclein cell-to-cell transfer in Parkinson's disease.
Angot E; Brundin P
Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S143-7. PubMed ID: 20082977
[TBL] [Abstract][Full Text] [Related]
17. A new perspective in Parkinson's disease, chaperone-mediated autophagy.
Li B; Zhang Y; Yuan Y; Chen N
Parkinsonism Relat Disord; 2011 May; 17(4):231-5. PubMed ID: 21215675
[TBL] [Abstract][Full Text] [Related]
18. Brain propagation of transduced α-synuclein involves non-fibrillar protein species and is enhanced in α-synuclein null mice.
Helwig M; Klinkenberg M; Rusconi R; Musgrove RE; Majbour NK; El-Agnaf OM; Ulusoy A; Di Monte DA
Brain; 2016 Mar; 139(Pt 3):856-70. PubMed ID: 26719384
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery.
Lee VM; Trojanowski JQ
Neuron; 2006 Oct; 52(1):33-8. PubMed ID: 17015225
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy in Parkinson's Disease: Micromanaging Alpha-Synuclein Aggregation.
George S; Brundin P
J Parkinsons Dis; 2015; 5(3):413-24. PubMed ID: 26406122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
